Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 64 of 64 results for hepatocellular carcinoma

  1. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Medtech innovation briefing
    Published
    30 March 2016

  2. Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

    This guidance has been updated and replaced by NICE technology appraisal guidance 555.

    Technology appraisal guidance
    Published
    21 March 2018

  3. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Medtech innovation briefing
    Published
    30 March 2016

  4. Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

    This guidance has been updated and replaced by NICE technology appraisal guidance 849.

    Technology appraisal guidance
    Published
    24 May 2019